MX2022015003A - Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina. - Google Patents

Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.

Info

Publication number
MX2022015003A
MX2022015003A MX2022015003A MX2022015003A MX2022015003A MX 2022015003 A MX2022015003 A MX 2022015003A MX 2022015003 A MX2022015003 A MX 2022015003A MX 2022015003 A MX2022015003 A MX 2022015003A MX 2022015003 A MX2022015003 A MX 2022015003A
Authority
MX
Mexico
Prior art keywords
dosage forms
oral dosage
solid oral
gonadotropin
releasing hormone
Prior art date
Application number
MX2022015003A
Other languages
English (en)
Inventor
David E Alonzo
Kathleen D Ullmer
Minli Xie
Original Assignee
Myovant Sciences Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myovant Sciences Gmbh filed Critical Myovant Sciences Gmbh
Publication of MX2022015003A publication Critical patent/MX2022015003A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)

Abstract

La presente descripción incluye formas de dosificación oral sólidas de combinación que tienen 40 mg de N-(4-(1-(2,6-difluorobe ncil)-5-((dimetilamino)metil)-3-(6-metoxi-3-piridazinil)-2,4-diox o-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il)fenil)-N'-metoxiur ea, o una cantidad correspondiente de una sal farmacéuticamente aceptable de esta, y medicamentos de reemplazo hormonal; también se proporcionan procesos para elaborar y usar las formas de dosificación oral sólidas.
MX2022015003A 2020-05-29 2021-05-27 Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina. MX2022015003A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063032469P 2020-05-29 2020-05-29
PCT/EP2021/064280 WO2021239917A1 (en) 2020-05-29 2021-05-27 Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists

Publications (1)

Publication Number Publication Date
MX2022015003A true MX2022015003A (es) 2023-03-03

Family

ID=76305879

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022015003A MX2022015003A (es) 2020-05-29 2021-05-27 Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.

Country Status (17)

Country Link
US (1) US20230165800A1 (es)
EP (1) EP4157227A1 (es)
JP (1) JP2023528014A (es)
KR (1) KR20230028732A (es)
CN (1) CN115666531A (es)
AR (1) AR122175A1 (es)
AU (1) AU2021278303A1 (es)
BR (1) BR112022023937A2 (es)
CA (1) CA3185151A1 (es)
CL (1) CL2022003338A1 (es)
CO (1) CO2022019160A2 (es)
EC (1) ECSP22098275A (es)
IL (1) IL298587A (es)
MX (1) MX2022015003A (es)
PE (1) PE20230859A1 (es)
UY (1) UY39229A (es)
WO (1) WO2021239917A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63300B1 (sr) 2016-09-30 2022-07-29 Myovant Sciences Gmbh Postupci lečenja fibroida materice i endometrioze
CN115227648B (zh) * 2022-08-03 2023-09-29 南昌大学 一种瑞卢戈利固体自微乳及其制备方法和应用
CN115068421B (zh) * 2022-08-03 2023-08-04 南昌大学 一种瑞卢戈利纳米混悬液及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0407082C1 (pt) 2003-01-29 2021-05-25 Takeda Pharmaceuticals Co composto n-(4-(1-(2,6-difluorobenzil)-5-((dimetilamino)metil)-3-(6-metóxi-3-piridazinil)-2,4-dioxo-1,2,3,4-tetraidrotieno[2,3-d]pirimidina-6-il)fenil)-n’-metoxiuréia, ou um sal do mesmo, produto farmacêutico, e, uso do composto
DK3415517T3 (da) 2012-09-28 2022-05-30 Takeda Pharmaceuticals Co Krystallinsk form af 1-(4-1-(2,6-difluorbenzyl)-5-dimethylaminomethyl-3-(6- methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)-pyrimidin- 6yl)phenyl)-3-methoxyurea
MY180680A (en) 2015-02-26 2020-12-06 Takeda Pharmaceuticals Co Solid preparation
RS63300B1 (sr) 2016-09-30 2022-07-29 Myovant Sciences Gmbh Postupci lečenja fibroida materice i endometrioze
EP3518932A2 (en) 2016-09-30 2019-08-07 Myovant Sciences GmbH Treatment of prostate cancer

Also Published As

Publication number Publication date
BR112022023937A2 (pt) 2022-12-27
CN115666531A (zh) 2023-01-31
JP2023528014A (ja) 2023-07-03
AR122175A1 (es) 2022-08-24
CA3185151A1 (en) 2021-12-02
WO2021239917A1 (en) 2021-12-02
EP4157227A1 (en) 2023-04-05
US20230165800A1 (en) 2023-06-01
ECSP22098275A (es) 2023-01-31
CO2022019160A2 (es) 2023-03-27
KR20230028732A (ko) 2023-03-02
PE20230859A1 (es) 2023-05-30
UY39229A (es) 2021-12-31
IL298587A (en) 2023-01-01
AU2021278303A1 (en) 2023-02-09
CL2022003338A1 (es) 2023-06-30

Similar Documents

Publication Publication Date Title
MX2022015003A (es) Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina.
EP2021006B1 (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2018060463A3 (en) Treatment of prostate cancer
GEP20074208B (en) Substituted amides active at the cannabinoid-1 receptor
NO2014032I1 (no) (E)-4-[[4-[[4-(2-cyanoetenyl)-2,6-dimetylfenyl-amino]--2-pyrfmidinyl]-amino]-benzonitril Rilpivirine) samt enhver terapeutisk ekvivalent form derav som er beskyttet av det aktuelle patentet så som farmasøytisk akseptable salter innbefattende hydrokloridsaltet av Rilpiverine; tenofovir og spesielt tenofovirdisproksilfumatat og emtricitabine.
RU2233273C3 (ru) Ароматические азотсодержащие 6-членные циклические соединения и фармацевтическая композиция
GEP20074124B (en) Azaindole kinase inhibitors
GEP20063875B (en) Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist
IL165264A (en) Protein kinase inhibitors, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating protein kinase-associated diseases
IT1271495B (it) Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
PH12021550687A1 (en) Pharmaceutical composition for oral administration comprising aminopyrimidine derivative or its salt
TNSN06349A1 (en) An antimycobacterial pharmaceutical composition
EP2455080A1 (en) S1P1 receptor agonists for use in the treatment of multiple sclerosis
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
AR038858A1 (es) Combinacion
CA2727722A1 (en) Use of dihydroimidazolones for the treatment of anxiety in dogs
WO2007083096A3 (en) N- (2, 3-difluorophenyl) -2- [4- ( {7-methoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazoli n-4-yl}amino) -lh-pyrazol-1-yl] acetamide and n- (2, 3 -d i fluoro phenyl) -2- [4- ( {7-ethoxy-5- [ (2r) -piperidin. -2-ylmethoxy] quinazolin
IL152613A0 (en) Novel vitronectin receptor antagonists
EP1652521A1 (en) Pharmaceutical composition of sildenafil and a large conductance Ca(2+) activated K+ channels activator
SE0400968D0 (sv) Aryl glycine ether derivatives and their use